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Abstract
Background: There is increasing evidence that tight blood glucose (BG) control improves outcomes in critically ill
adults. Children show similar hyperglycaemic responses to surgery or critical illness. However it is not known
whether tight control will benefit children given maturational differences and different disease spectrum.
Methods/Design: The study is an randomised open trial with two parallel groups to assess whether, for children
undergoing intensive care in the UK aged ≤ 16 years who are ventilated, have an arterial line in-situ and are receiving
vasoactive support following injury, major surgery or in association with critical illness in whom it is anticipated such
treatment will be required to continue for at least 12 hours, tight control will increase the numbers of days alive and
free of mechanical ventilation at 30 days, and lead to improvement in a range of complications associated with
intensive care treatment and be cost effective.
Children in the tight control group will receive insulin by intravenous infusion titrated to maintain BG between 4 and
7.0 mmol/l. Children in the control group will be treated according to a standard current approach to BG management.
Children will be followed up to determine vital status and healthcare resources usage between discharge and 12
months post-randomisation. Information regarding overall health status, global neurological outcome, attention
and behavioural status will be sought from a subgroup with traumatic brain injury (TBI).
A difference of 2 days in the number of ventilator-free days within the first 30 days post-randomisation is consid-
ered clinically important. Conservatively assuming a standard deviation of a week across both trial arms, a type I
error of 1% (2-sided test), and allowing for non-compliance, a total sample size of 1000 patients would have 90%
power to detect this difference. To detect effect differences between cardiac and non-cardiac patients, a target
sample size of 1500 is required. An economic evaluation will assess whether the costs of achieving tight BG control
are justified by subsequent reductions in hospitalisation costs.
Discussion: The relevance of tight glycaemic control in this population needs to be assessed formally before
being accepted into standard practice.
Trial Registration: Current Controlled Trials ISRCTN61735247
Background
The ability to control blood sugar is known to be
impaired in patients subjected to the stress of major sur-
gery or critical illness resulting in high blood sugar
levels (hyperglycaemia)[1]. This may in part result from
insulin resistance, as insulin-dependent glucose uptake
has been shown to be reduced in various organs and tis-
sues during critical illness. Glucose uptake is however
increased in non-insulin dependent tissues such as
brain, red blood cells and wounds. This imbalance of
glucose metabolism has previously been interpreted as
the body’s plea for tolerating moderately high levels of
glucose during critical illness and injury and treatment
of ‘stress-induced’ hyperglycaemia has typically only* Correspondence: D.macrae@rbht.nhs.uk
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been initiated if BG levels are persistently and substan-
tially elevated.
Hyperglycaemia in Critically Ill Adults
Over recent years several studies have associated hyper-
glycaemia with adverse outcomes during acute illness in
adults:
Myocardial infarction
In a meta-analysis [2], patients with acute myocardial
infarction without diabetes who had glucose concentra-
tions more than or equal to range 6.1-8.0 mmol/L had a
3.9-fold (95% CI 2.9-5.4) higher risk of death than
patients without diabetes who had lower glucose con-
centrations. Glucose concentrations higher than values
in the range of 8.0-10.0 mmol/L on admission were
associated with increased risk of congestive heart failure
or cardiogenic shock in patients without diabetes. Stress
hyperglycaemia with myocardial infarction is associated
with an increased risk of in-hospital mortality and
increased risk of congestive heart failure or cardiogenic
shock in patients without diabetes.
Stroke
Capes et al. conducted a systematic review and meta-
analysis of the literature relating acute post stroke glu-
cose levels to the subsequent course [3]. A comprehen-
sive literature search was done for cohort studies
reporting mortality and/or functional recovery after
stroke in relation to admission glucose level. Thirty-
two studies were identified for which pre-defined out-
comes could be analysed in 26. After stroke, the unad-
justed relative risk of in-hospital or 30-day mortality
associated with admission glucose level >6 to 8 mmol/
L was 3.07 (95% CI, 2.50 to 3.79) in non-diabetic
patients and 1.30 (95% CI, 0.49 to 3.43) in diabetic
patients. Non-diabetic stroke survivors whose admis-
sion glucose level was >6.7 to 8 mmol/L also had a
greater risk of poor functional recovery (relative risk =
1.41; 95% CI, 1.16 to 1.73).
Head injury and multi-system trauma
Hyperglycaemia has been shown to be an independent
predictor of poor outcome in adult patients[4] and chil-
dren with head injury[5,6] and multiple trauma[7].
Pulmonary function
Hyperglycaemia has been shown to be associated with
diminished pulmonary function in adults even in the
absence of diabetes mellitus[8] and a range of other
effects with potential to injure the lung[9].
Gastrointestinal effects
Hyperglycaemia has been shown to be associated with
delayed gastric emptying[10], decreased small bowel
motility and to increase sensation and cerebral evoked
potentials to a range of gastrointestinal stimuli in adult
volunteers [11-14].
Infections
In vitro responsiveness of leukocytes stimulated by
inflammatory mediators is inversely correlated with gly-
caemic control[15]. This reduction in polymorphonuc-
lear leucocyte responsiveness may contribute to the
compromised host defence associated with sustained
hyperglycaemia[15], and indeed, hyperglycaemia has
been shown to be associated with an increased rate of
serious infections after adult cardiac[16] and vascular
[17] surgery.
Studies of Control of Glycaemia in Adults
Recent reports from adult populations suggest that con-
trol of glycaemia during acute illness can be associated
with improved outcomes[18-22].
Furnary[21] studied the hypothesis that since hyper-
glycaemia was associated with higher sternal wound
infection rates following adult cardiac surgery, aggressive
control of glycaemia might lead to lower infection rates.
In a prospective study of 2,467 consecutive diabetic
patients who underwent open heart surgical procedures,
patients were classified into two sequential groups. A
control group included 968 patients treated with sliding-
scale-guided intermittent subcutaneous insulin injec-
tions. A study group included 1,499 patients treated
with a continuous intravenous insulin infusion in an
attempt to maintain a BG level of less than 11.1 mmol/l.
Compared with subcutaneous insulin injections, contin-
uous intravenous insulin infusion induced a significant
reduction in perioperative BG levels, which led to a sig-
nificant reduction in the incidence of deep sternal
wound infection in the continuous intravenous insulin
infusion group (0.8% [12 of 1,499]) versus the intermit-
tent subcutaneous insulin injection group (2.0% [19 of
968], p = 0.01). The use of perioperative continuous
intravenous insulin infusion in diabetic patients under-
going open heart surgical procedures appears to signifi-
cantly reduce the incidence of major infections.
Malmberg[19] randomly allocated patients with dia-
betes mellitus and acute myocardial infarction to inten-
sive insulin therapy (n = 306) or standard treatment
(controls, n = 314). The mean (range) follow up was 3.4
(1.6-5.6) years. There were 102 (33%) deaths in the
treatment group compared with 138 (44%) deaths in the
control group (relative risk (95% confidence interval)
0.72 (0.55 to 0.92); p = 0.011). The effect was most pro-
nounced among the predefined group that included 272
patients without previous insulin treatment and at a low
cardiovascular risk (0.49 (0.30 to 0.80); p = 0.004).
Intensive insulin therapy improved survival in diabetic
patients with acute myocardial infarction. The effect
seen at one year continued for at least 3.5 years, with an
absolute reduction in mortality of 11%.
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In 2001 Van den Berghe and colleagues from Leuven,
Belgium[18] reported the results of a randomised trial in
adults undergoing intensive care following surgical pro-
cedures. This trial showed that the use of insulin to
tightly control BG led to a reduction in mortality (32%),
mean length of intensive care stay (22%), and signifi-
cantly lower occurrence of a range of complications of
critical illness such as renal failure, infection, inflamma-
tion, anaemia and polyneuropathy. Duration of intensive
care stay was 3.4 days shorter in the insulin group.
Recently the Leuven group[22] have reported that, in
addition to adult surgical intensive care patients, inten-
sive insulin therapy reduces morbidity in adults who
require intensive care for treatment of medical condi-
tions. In this prospective randomised controlled trial,
patients were randomly assigned to a regime of strict
normalisation of BG (4.4-6.1 mmol/l) with use of insu-
lin, or conventional therapy where insulin is adminis-
tered only when BG levels exceeded 12 mmol/l, with
the infusion tapered when the level fell below 10 mmol/
l. In the intention to treat analysis of the 1200 patients
included, ICU and in-hospital mortality were not signifi-
cantly altered by intensive insulin therapy, however for
those patients requiring more than 3 days intensive
care, mortality was significantly reduced from 52.5 to
43% (p = 0.009). Morbidity was significantly reduced by
intensive insulin therapy with a lower incidence of renal
injury and shorter length of mechanical ventilation and
duration of hospital stay noted. Beyond the fifth day of
intensive insulin therapy, all morbidity endpoints were
beneficially affected, whereas for those patients staying
less than 3 days, none of the morbidity end-points were
significantly different between the two treatment groups.
On the basis of these studies, several groups have
recommended that tight glycaemic control with inten-
sive insulin therapy become a standard of care for the
critically ill adult patients. The Joint Commission on
Accreditation of Healthcare Organization (JACHO)
recently proposed tight glucose control for the critically
ill as a core quality of care measure for all U.S. hospitals
that participate in the Medicare program[23]. The Insti-
tute for Healthcare Improvement, together with an
international initiative by several professional societies
including the American Thoracic Society, is promoting
a care “bundle” for severe sepsis that also includes
intensive glycaemic control for critically ill adults[24].
Both the Society of Critical Care Medicine and Eur-
opean Society of Intensive Care Medicine have incorpo-
rated TGC into their recently publicised ‘Surviving
Sepsis’ guidelines. These initiatives represent important
attempts to translate research findings into improved
care at the bedside[25].
The possible mechanisms by which different glucose
control strategies might influence clinical outcomes are
yet to be fully elucidated. There is a substantial body of
published research which points to an association
between hyperglycaemia and organ/tissue dysfunction.
In models of both focal and global cerebral ischaemia,
hyperglycaemia has been shown to be associated with
exacerbation of intracellular acidosis[26-28], accumula-
tion of extracellular glutamate[29], cerebral oedema for-
mation and disruption[30]of the blood-brain barrier[31].
In ischaemic brain injury, hyperglycaemia may worsen
injury by promoting anaerobic metabolism and conse-
quent intracellular acidosis. In the rat myocardium,
hyperglycaemia leads to up-regulation of inducible nitric
oxide synthase, resulting ultimately in an increase in
production of superoxide, a condition favouring the pro-
duction of the powerful pro-oxidant peroxynitrite. This
highly reactive free radical has the power to cause direct
oxidant damage to myocardial cells or to induce myo-
cardial cell apoptosis[32,33]. Similar adverse mechan-
isms have been shown to exist in hyperglycaemic
patients [34,35]. Improved clinical outcomes may arise
not necessarily solely as a result of control of BG. Insu-
lin lowers free fatty acids and normalises endothelial
function[36], is associated with anabolic effects[37,38],
has been shown to have anti-inflammatory effects[39,40]
and to have cardio-protective effects[41], all of which
may contribute independently to better outcomes in cri-
tical illness.
Hyperglycaemia in Critically Ill Children
Over 10,000 children are admitted to intensive care
units in England and Wales each year[42]. Hyperglycae-
mia, defined as BG > 7 mmol/l, occurs frequently during
critical illness or after major surgery in children, with a
reported incidence of up to 86%[43]. As in adults, the
occurrence of hyperglycaemia has been shown to be
associated with poorer outcomes including death, sepsis,
and longer length of intensive care stay in critically ill
children[43-46]. Non-randomised research in children
includes a number of reports from general[43-45,47]
and cardiac PICUs[46] showing that high BG levels
occur frequently in critically ill children and that BG
levels are significantly higher in children who die than
in children who survive.
Srinivasan[43] studied the association of timing, dura-
tion, and intensity of hyperglycaemia with PICU mortal-
ity in critically ill children. The study was a
retrospective, cohort design and included 152 critically
ill children receiving vasoactive infusions or mechanical
ventilation. Peak BG of > 7 mmol/L occurred in 86% of
patients. Compared with survivors, non-survivors had
higher peak BG (17.3 mmol/L +/- 6.4 vs. 11.4 +/- 4.4
mmol/L, p <.001). Non-survivors had more intense
hyperglycaemia during the first 48 hrs in the PICU (7
+/-2.1 mmol/L) vs. survivors (6.4 +/- 1.9 mmol/L, p
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<.05). Univariate logistic regression analysis showed that
peak BG and the duration and intensity of hyperglycae-
mia were each associated with PICU mortality (p <.05).
Multivariate modelling controlling for age and Paediatric
Risk of Mortality scores showed independent association
of peak BG and duration of hyperglycaemia with PICU
mortality (p <.05). This study demonstrated that hyper-
glycaemia is common among critically ill children. Peak
BG and duration of hyperglycaemia appear to be inde-
pendently associated with mortality. The study was lim-
ited by its retrospective design, its single-centre location
and the absence of cardiac surgical cases, a group which
make up approximately 40% of paediatric intensive care
(PICU) admissions in the UK.
Halverson-Steele[46] has recently shown in a retro-
spective study, that hyperglycaemia was associated with
poor outcomes in 526 children following cardiac sur-
gery. Nineteen patients (3.6%) died postoperatively
(median 11 days, range 1-17 days). Peak plasma glucose
concentrations in survivors (mean 10.7 mmol/l, SD 3.7)
was significantly lower than the peak value recorded in
non-survivors (mean 14.3 mmol/l, SD 4.2; p = 0.0017).
The 147 patients who were discharged from ICU within
24 hours had lower plasma glucose concentrations on
admission (mean 7.5 mmol/l, SD 2.3) and peak plasma
glucose concentrations (mean 9.2 mmol/l, SD 2.3) than
the remaining patients staying longer than 24 hours
(mean 8.1 mmol/l, SD 4.0; p = 003 and mean 11.3
mmol/l, SD 3.9; p < 0.0001, respectively). Peak plasma
glucose concentrations were also lower in 387 patients
admitted for up to 5 days (mean 10.1 mmol/l, SD 2.9)
when compared with those patients with ICU stays of >
5 days (mean 12.7 mmol/l/, SD 4.6; p < 0.0001).
Hall[45] investigated the incidence of hyperglycaemia
in infants with necrotizing enterocolitis (NEC) and the
relationship between glucose levels and outcome in
these infants. Glucose measurements (n = 6508) in 95
neonates with confirmed NEC admitted to the surgical
intensive care unit were reviewed. Glucose levels ranged
from 0.5 to 35.0 mmol/L. 69% of infants became hyper-
glycaemic (>8 mmol/L) during their admission. Thirty-
two infants died. Mortality rate tended to be higher in
infants when maximal glucose concentration exceeded
11.9 mmol/L compared with those with maximum glu-
cose concentrations of less than 11.9 mmol/L, and late
(>10 days admission) mortality rate was significantly
higher in these infants (29% v, 2%; p = .0009). Linear
regression analysis indicated that maximum glucose
concentration was significantly related to length of stay
(p <.0001).
Branco[44] showed that there is an association
between hyperglycaemia and increased mortality in chil-
dren with septic shock. They prospectively studied all
children admitted to a regional PICU with septic shock
refractory to fluid therapy over a period of 32 months.
The peak glucose level in those with septic shock was
11.9 +/- 5.4 mmol/L (mean +/- SD), and the mortality
rate was 49.1% (28/57). In non-survivors, the peak glu-
cose level was 14.5 +/- 6.1 mmol/L, which was higher (p
<.01) than that found in survivors (9.3 +/- 3.0 mmol/L).
The relative risk of death in patients with peak glucose
levels of ≥ 9.9 mmol/L was 2.59 (range, 1.37-4.88).
Faustino[47] demonstrated that hyperglycaemia occurs
frequently among critically ill non-diabetic children and
is associated with higher mortality and longer lengths of
stay. They performed a retrospective cohort study of
942 non-diabetic patients admitted to a PICU over a 3
year period. The prevalence of hyperglycaemia was
based on initial PICU glucose measurement, highest
value within 24 hours, and highest value measured dur-
ing PICU stay up to 10 days after the first measurement.
Through the use of three cut-off values (6.7 mmol/L, 8.3
mmol/L, and 11.1 mmol/L), the prevalence of hypergly-
caemia was 16.7% to 75.0%. The relative risk (RR) for
dying increased for maximum glucose within 24 hours
>8.3 mmol/L (RR, 2.50; 95% confidence interval (CI),
1.26 to 4.93) and highest glucose within 10 days >6.7
mmol/L (RR, 5.68; 95% CI, 1.38 to 23.47).
Pham[48] have recently reported their experience of
adopting a policy of ‘intensive’ insulin therapy to achieve
BG levels 5 mmol/L to 6.7 mmol/L. They reviewed the
records of children with ≥ 30% total body surface area
burn injury admitted over a 3 year period. The first
cohort of 31 children received ‘conventional insulin
therapy’, whilst the subsequent cohort of 33 children
received ‘intensive insulin therapy’. The demographic
characteristics and injury severity were similar between
the groups. Intensive insulin therapy was positively asso-
ciated with survival and a reduced incidence of infec-
tions. The authors therefore concluded that intensive
insulin therapy to maintain normoglycaemia in severely
burned children could be safely and effectively imple-
mented in a paediatric burns unit and that this therapy
seemed to lower infection rates and improve survival.
There is therefore mounting evidence to suggest that a
policy of TGC may be beneficial to neonates and chil-
dren undergoing neonatal and paediatric intensive care,
but none of this evidence is from large rigorous rando-
mized controlled trials. The aim of the present study is
to determine whether a policy of strictly controlling BG
using insulin in children admitted to paediatric intensive
care reduces mortality, morbidity and is cost-effective.
Methods/Design
Study Design
The study is an individually randomised controlled open
trial with two parallel groups. The protocol is sum-
marised in Figure 1.
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Figure 1 Flow diagram of the CHiP Trial Protocol.
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Main hypothesis
For children aged from birth to ≤ 16 years on ventila-
tory support and vasoactive support drugs, tight glucose
control (TGC) will increase the numbers of days alive
and free of mechanical ventilation at 30 days.
Secondary hypotheses
That TGC will lead to improvement in a range of com-
plications associated with intensive care treatment and
be cost effective.
Setting
The following PICUs in the United Kingdom (UK) will
be recruiting patients into the CHiP trial: Birmingham
Children’s Hospital; Bristol Royal Hospital for Children;
Great Ormond Street Hospital; Leeds General Infirmary;
University Hospitals of Leicester - Glenfield Hospital;
Royal Brompton & Harefield NHS Trust (Royal Bromp-
ton Hospital); Royal Liverpool Children’s NHS Trust;
Royal Manchester Children’s Hospital; St Mary’s Hospi-
tal; Sheffield Children’s NHS Foundation Trust; South-
ampton General Hospital; University Hospital of North
Staffordshire.
Ethical Approval
MREC approval obtained from the Brighton East
Research Ethics Committee (re 07/Q1907/24) in 2007
and SSIs have been successfully completed for all 10
participating centres. Over 500 children have thus far
been recruited.
Type of participants
Inclusion criteria
Children from birth (≥ 36 weeks corrected gestation) to
≤ 16 years who are undergoing treatment on a PICU
with an arterial line in-situ and who are receiving both
mechanical ventilation and vasoactive drugs (Table 1)
following injury, major surgery or in association with
critical illness in whom it is anticipated that such treat-
ment will be required to continue for at least 12 hours.
Exclusion criteria prior to trial entry
• Children born pre-term and who are < 36 weeks
corrected gestation
• Children with diabetes mellitus
• Children with an established or suspected diagno-
sis of an inborn error of metabolism
• Children for whom treatment withdrawal or limita-
tion of intensive care treatment is being considered
• Children who have been in a PICU for more than
5 days
• Children admitted to a PICU who have already
participated in the CHIP study during a previous
PICU admission.
Consent
Parents/guardians of babies and children in intensive
care are likely to be stressed and anxious. However they
will be asked to give consent in their role of legal repre-
sentatives and will usually have limited time to consider
trial entry as it may not be medically appropriate to
delay the start of treatment. Parents of babies and chil-
dren listed for cardiac surgery will be given information
about the trial pre-operatively and consent provisionally
obtained to be confirmed later if the child is admitted
to intensive care. In addition, where possible, older chil-
dren will be given information and asked to assent to
their participation in the study.
Patients not entered into the trial will receive standard
care
Allocation
To reduce the risk of selection bias at trial entry, alloca-
tion will be administered through a 24 hour, 7 day a
week central randomisation service. Minimisation with a
probabilistic element will be used to ensure a balance of
key prognostic factors between groups using the follow-
ing criteria:
• Centre
• Age ≤ 1 year versus between 1 year and ≤ 16 years
• Admitted following cardiac surgery or not
• For cardiac surgical children, Risk adjusted classifi-
cation for Congenital Heart Surgery 1 (RACHS1)[49]
category 1 to 4 versus 5 to 6
• For non-cardiac surgical children, Paediatric index
of mortality version 2 (PIM2) score at randomization
categorised by probabilities of death of <5%, 5% -
<15% and ≥ 15%
• Accidental TBI or not
Interventions
After inclusion in the study, children will be randomised
to one of two groups: Group 1 (Standard treatment) or
Group 2 (Tight glycaemic control).
Group 1 - Standard treatment
Children in this group will be treated according to a
standard, current, approach to BG management. Insulin
will be given by intravenous infusion in this group only
if BG levels exceed 12 mmol/l on two blood samples
Table 1 Definition of vaso-active drugs
Vaso-active drug name Dose
Dobutamine > 5 mcg/kg/min
Dopamine > 5 mcg/kg/min
Epinephrine Any dose
Norepinephrine Any dose
Milrinone Any dose
Vasopressin Any dose
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taken at least 30 minutes apart and will be discontinued
once BG falls to <10 mmol/l. A protocol for glucose
control in this group is in Figure 2.
Group 2 - Tight glycaemic control
Children in this group will receive insulin by intrave-
nous infusion titrated to maintain a BG between the
limits of 4 and 7.0 mmol/l. A protocol for glucose con-
trol in this group is in Figure 3.
The protocol for glucose control in group 2 has been
carefully designed to achieve tight glucose control
whilst minimizing the risk of hypoglycaemia, the prin-
cipal side effect of insulin therapy. Standard insulin
solutions will be used and changes in insulin infusion
rates will be guided both by the BG and its rate of
change from previous measurements. BG levels will be
routinely measured as in all PICUs using commercially
available ‘point of care’ analysers which utilise very
small blood samples, producing results in approxi-
mately 1 minute. Analysers are rigorously maintained
and subjected to laboratory-standard quality assurance
programmes.
Training in use of the BG control protocol will be
provided before the first patient is enrolled in each col-
laborating centre and for new staff throughout the trial.
The Clinical Co-ordinating centre team will liaise closely
with local clinicians to ensure that BG control algo-
rithms are followed closely and safely.
Outcome measures
Primary outcome
Following the influential ARDSNET study[50] the pri-
mary outcome for CHiP trial is the number of days alive
and free from mechanical ventilation within the 30 days
after trial entry. Death is obviously an important out-
come. Mechanical ventilation can be seen as a measure
of disease severity, defining the need for complex inten-
sive care. The concept of ventilator free days (VFDs)
brings together these two outcomes. Schoenfeld[51]
define VFDs as: VFD = 0 if the child dies before 30
days; VDF = (30-x) if the child is successfully weaned
from ventilator within 30 days (where × is the number
of days on ventilator); or VFD = 0 if the child is
Figure 2 Algorithm for the titration of insulin in the normal control group.
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ventilated for 30 days or more. The use of organ failure
free days to determine patient-related morbidity surro-
gate end-points in paediatric trials has been supported
by influential paediatric trialists in the current low mor-
tality paediatric critical care environment[52].
Secondary outcomes
Death within 30 days after trial entry (or before dis-
charge from hospital if duration is greater than 30 days)
Death within 12 months of trial entry
Number of days in PICU
Duration of mechanical ventilation
Duration of vasoactive drug usage (adrenaline, nora-
drenaline, dopamine, dobutamine, or Phoshopdiesterase
type III [PDEIII] inhibitors or vasopressors)
Need for renal replacement therapy
Blood stream infection (positive cultures associated
with two or more features of systemic inflammation or
any positive blood culture for bacteria or fungi)
Use of antibiotics >10 days
Number of red cell transfusions
Number of hypoglycaemic episodes moderate (≤ 2.5
mmol/L), severe (≤ 2.0 mmol/L)
Occurrence of seizures (clinical seizures requiring
anticonvulsant therapy)
Paediatric logistic organ dysfunction (PELOD) score
[52-54],
Hospital length of stay
Number of children readmitted to PICU within 30
days of trial entry
Cost and cost-effectiveness measures
Hospital costs within 30 days of trial entry
Cost per life year (based on 30 days costs and survival)
Hospital and community health service costs within 12
months of trial entry
Cost per life year (based on 12 month costs and survi-
val for all cases)
Cost per disability-free survivor (based on 12 month
cost and outcome data for sub group with traumatic
brain injury)
Follow-up at 12 months
If parents give their consent, all children surviving to
hospital discharge will be followed up to 12 months
post-randomisation to determine mortality using the
NHS Central Register of the Office of National Statistics
Figure 3 Algorithm for the titration of insulin in the tight control group.
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(ONS). Parents will be informed about the follow-up
study at trial entry and asked to give consent. The Trial
Manager at the Data Co-ordinating Centre (DCC) will
write to parents following discharge home to remind
them about the follow-up and ask them to keep the
DCC informed about any change of address. At hospital
discharge parents will be given a diary to help them
record their child’s service use post discharge. At around
11 months, following checks with the GP/Health Visitor
to determine that this is appropriate, the Trial Manager
will send a questionnaire to parents to determine the
use of health care resources between discharge and 12
months. Non-responders will be followed-up by letter
and telephone.
Follow-up of traumatic brain Injury sub-group
TBI is defined for this study as accidental trauma to the
head resulting in need for intubation and mechanical
ventilation. There are approximately 750 ICU admis-
sions per year in the UK, and an estimated 150 will be
recruited into CHiP.
This sub-group is more likely to have longer-term
morbidity and parents of children (aged 4 or over) in
this sub-group will be asked to provide additional infor-
mation at 12 months, regarding overall health status,
global neurological outcome, attention and behavioural
status.
Outcome assessment will comprise four components:
Overall health status: measured by the Health Utilities
Index (HUI)
Global neurological outcome: measured by the Kings
Outcome Scale for Childhood Head Injury (KOSCHI)
Attention and behavioural assessment: measured by
the Child Behavioural Check List (CBCL) and the Con-
nor’s Rating Scales revised - short version (CRS-R:S)
The HUI and KOSCHI will be completed using a
structured telephone interview (around 10 minutes).
The CBCL and CRS are both written questionnaires
that will be posted out to the families. They take
approximately 30 minutes to complete.
The Health Utilities Index is a multi-attribute health
status classification system. Seven attributes (sensation,
mobility, emotion, cognition, self-care, pain, fertility) are
categorised according to one of 4 or 5 levels. In this
population fertility will be excluded. The algorithm
(from death to perfect health scale) provides a single
numerical value.
KOSCHI is a 5 point categorical scale, ranging from
death to normal neurological function, and is similar in
structure to the Glasgow Outcome Scale, which is widely
used in adult studies. In addition the KOSCHI is further
subdivided into two subcategories at points 4 and 5 on the
scale (moderate outcome and good outcome). Patient out-
comes will be dichotomized between patients in categories
1, 2, 3, 4A and those in 4B, 5A, 5B.
Child behaviour checklist (CBCL/4-18) (problem
scales) is based on parental report and assesses proble-
matic child behaviour that is summarised in internalis-
ing behaviour (anxious/depressed, withdrawn/depressed,
somatic complaints), externalising behaviour (rule-
breaking, aggressive) and other (social problems,
thought problems, attention problems).
In reference to 1991 normative data (Table 2) Patient
outcome can be summarised according to placement
within one of the three groups, or according to the T-
score.
The Conners’ rating scales (revised - short version
CRS-R:S) assesses symptoms of attention-deficit/hyper-
activity disorder and related problem behaviour in chil-
dren and adolescents based on parent’s report.
In reference to 1993 normative data (Table 3) Patient
outcome can be summarised according to placement
within one of the three groups (marked + moderate,
mild + slight, average + good), or according to the T-
score.
Adverse events and safety reporting
The Royal Brompton & Harefield NHS Trust, as spon-
sor of this study, has responsibility to ensure arrange-
ments are in place to record, notify, assess, report,
analyse and manage adverse events in order to comply
with the UK regulations of Medicines for Human Use
(Clinical Trials) Regulations 2004.
All sites involved in the study are expected to inform
the Chief Investigator and Study nurse of any serious
adverse events/reactions within 24 hours so that appro-
priate safety reporting procedures can be followed by
the Sponsor.
Expected side effects
All adverse events judged by either the investigator or
the sponsor as having a reasonable suspected causal
relationship to insulin therapy qualify as adverse
reactions.
Whilst any suspected, unexpected, serious adverse
reaction (SUSAR) involving insulin therapy will be
reported according to the timelines for SUSARs,
expected side effects of insulin will be reported in the
annual safety report unless serious enough to warrant
expedited reporting.
The most prominent adverse effect of insulin treat-
ment is hypoglycaemia. This is particularly important in
Table 2 Child behavior checklist (CBCL/4-18) assessment
of outcome according to T-score
T-score (Whole) Guideline T-score (Individual scale) Guideline
<60 Normal <65 Normal
60-63 Borderline 65-69 Borderline
>63 Clinical >69 Clinical
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the TCG arm of the study which is aiming to control
BG within the range 4 - 7 mmol/l which is well above
the 2 mmol/l threshold for clinically important hypogly-
caemia [55]. The principal measure to avoid clinically
important hypoglycaemia will be hourly measurement of
BG when insulin is first administered. The insulin
administration protocols aim to achieve glucose control
with the lowest possible incidence of hypoglycaemia and
the avoidance of neuroglycopaenia. Hypoglycaemic
events will be reported to the Clinical Co-coordinating
Centre and if necessary, the BG control protocols will
be revised, whilst still aiming to achieve BG levels within
the target ranges.
Insulin is reported to occasionally cause a rash which
may be associated with itching.
Data collection
To minimise the data collection load for busy units, the
trial will collaborate with the Paediatric Intensive Care
Audit Network (PICANet http://www.picanet.org.uk) to
make best use of the established data collection infra-
structure which exists in all PICUs in the UK. The
PICANet dataset includes most of the items being used
in the trial and these data will be transmitted from the
participating centres to the Data Co-ordinating Centre
electronically using strong encryption. The remaining
short term data items will be collected locally by the
research nurses, and those for the longer term follow-up
will be collected separately by telephone and postal
questionnaires. These data will be double entered onto
electronic database storage systems at the Data Co-ordi-
nating Centre.
Economic evaluation
Cost-consequence and cost-effectiveness analyses will be
undertaken as part of the proposed study. These eco-
nomic evaluations will assess whether the costs of
achieving tight BG control are justified by subsequent
reductions in hospitalisation costs and/or by improve-
ments in patient outcomes. The evaluations will be con-
ducted in two phases, in the first phase all hospital costs
at 30 days post randomisation will be compared across
treatment groups alongside 30-day outcomes, in the sec-
ond phase cost and outcomes at 12-months will be
compared across the groups.
For the first phase evaluations, detailed resource use
data will be collected for each patient enrolled in CHIP
using the Paediatric Critical Care Minimum Dataset
(PCCMDS)[56] which will be collected by each PICANet
unit. Where information on resource use required in
CHIP is not available from these sources datasheets
similar to those developed as part of the INNOVO
study will be used [57]. Information will also be col-
lected on the resources required to achieve tight BG
control, in particular all medication use and the staff
time involved in monitoring the patients and managing
adverse events (e.g. hypoglycaemia) will be noted.
Unit costs for hospital services will be taken from the
NHS ‘payment by results’ database[58]. Where more
detailed unit costs are required, for example those asso-
ciated with staff time and the use of insulin infusion,
these will be collected on site visits to centres. Hospital
costs up to 30 days will be estimated by valuing each
resource use item by the appropriate unit cost.
In the second phase of the study the time horizon of
the economic evaluation will be extended to 12 months,
and resource use data for hospital re-admissions, outpa-
tient visits and the use of community health services
will be collected for all cases. For the sub-sample of
patients diagnosed as having traumatic brain injury at
study entry, information on the patient’s disability at
one-year will be collected during telephone interviews
with the patients’ relatives based on previously devel-
oped interview schedules [57]. All community service
use will be valued using national unit costs[59]. Total
costs for each patient will be calculated by summing the
costs of all hospital and community health services used.
All the economic analyses will be based on the treat-
ment groups as randomly allocated (’intention to treat’).
The initial analysis will include a cost-consequence ana-
lysis and will report mean differences (95% CI) between
treatment groups in resource use (e.g. length of hospital
stay) and total hospital costs per patient, alongside the
primary clinical endpoint. The initial analysis will also
combine costs and outcomes at 30 days post-randomisa-
tion in a cost-effectiveness analysis, which will report
cost per death averted and cost per adverse event
averted. The subsequent analysis will use 12-month cost
and outcome data to report the cost per death averted
for all patients. For the sub-sample of patients diagnosed
as having brain injury at study entry, the cost-effective-
ness analysis will also report the cost per death or dis-
abled case averted.
The sensitivity analysis will test whether the results
are robust to key assumptions made, for example to the
choice of unit costs and the time horizon of the analysis.
Table 3 The Conner’s’ rating scales (revised - short
version CRS-R:S) assessment of outcome according to T-
score
T-score Guideline
≥ 70 Markedly atypical (significant problem)
66-69 Moderately atypical (significant problem)
61-65 Mildly atypical (possible significant problem)
56-60 Slightly atypical (borderline)
45-55 Average (no concern)
≤ 44 Good
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The cost and outcome data collected at one-year will be
used to project the impact of the intervention on
longer-term costs and outcomes.
Sample size
A difference of 2 days in the number of ventilator-free
days (VFD) within the first 30 days post-randomisation
between the two groups has been chosen as the primary
outcome measure for the trial. Information from PICA-
Net using data from UK PICUs for 2003-4 estimates
that the mean number of VFDs in cardiac patients is
26.7, with a standard deviation (SD) of 4.2. Correspond-
ing figures for non-cardiac patients are a mean of 22.7
days, with a standard deviation (SD) of 6.8 days. As the
SD is estimated with error, to be conservative we have
assumed the SD is nearer 5.5 days for the cardiac and 8
days for the non-cardiac patients. There are likely to be
more non-cardiac than cardiac patients eligible for the
trial. We have therefore assumed an overall SD across
both cardiac and non-cardiac strata of 7 days. Assuming
this is the same in both trial arms, and taking a type I
error of 1% (with a 2-sided test), a total sample size of
750 patients would have 90% power to detect this differ-
ence. Whereas we can assume minimal loss to follow up
to 30 days, there may be some non-compliance (some
patients allocated to tight control not receiving this, and
some allocated to usual care being managed with tight
control). The target size will therefore be inflated to
1000 to take account of possible dilution of effect.
As information from PICANet indicates that there are
differences in outcome between cardiac and non-cardiac
patients not merely in VFDs but also in 30 day mortality
rate (3.4% vs. 20%) and mean duration of time on a venti-
lator (3.7 vs. 8.0 days, survivors and non-survivors com-
bined), we also wish to be able to detect whether any
effect of tight glucose control differs between the cardiac
and non-cardiac strata. To have 80% power for an interac-
tion test to be able to detect a difference of two days in
the effect of intervention between the strata at the 5%
level of statistical significance, we would need to increase
the sample size to 1500. If the interaction test was positive
this size would allow us to assess the effect of tight glucose
control separately in the two strata.
Recruitment rate
There are approximately 1300 cardiac and 1550 non-car-
diac eligible patients per year in the collaborating PICUs.
If half of those eligible are recruited into the trial, it
should be feasible to recruit the overall total sample size
of 1500 within the 24 months recruitment period.
Type of analysis
Analysis will be by intention to treat. The following sub-
group analyses will be conducted; age (Age ≤ 1 year ver-
sus between 1 year and ≤ 16 years), severity of illness,
traumatic brain injury or not, cardiac surgical versus
non-cardiac cases, RACHS1 (cardiac cases) (Groups 1-4
versus 5 and 6), PIM2 group (non-cardiac cases) (cate-
gorised by probabilities of death of <5%, 5% - <15% and
≥ 15%), run in cases v. non-run in cases.
Frequency of analysis
An independent Data Monitoring and Ethics Committee
(DMEC) will review, in strict confidence, data from the
trial approximately half way through the recruitment
period. The Chair of the DMEC may also request addi-
tional meeting/analyses. In the light of these data and
other evidence from relevant studies, the DMEC will
inform the Steering Committee if in their view:
i. There is proof that the data indicate that any part
of the protocol under investigation is either clearly
indicated or clearly contra-indicated either for all
patients or a particular subgroup of patients. using
the Peto and Haybittle rule [60,61]
ii. It is evident that no clear outcome will be
obtained with the current trial design.
iii. That they have a major ethical or safety concern
Ancillary studies
In addition to the main study, some collaborators may
wish to conduct other more detailed or complementary
studies. The grant holders welcome this provided that
proposals are discussed in advance with the Trial Steer-
ing Committee and appropriate additional Research
Ethics approval is sought.
Organisation
The Trial Steering Committee (TSC) responsibilities are
to approve the main study protocol and any amend-
ments, monitor and supervise the trial towards its
interim and overall objectives, review relevant informa-
tion from other sources, consider the recommendations
of the DMEC, and resolve problems brought by the trial
co-coordinating centres. Day to day management of the
trial will be overseen by a Trial Management Group
(TMG) comprising the grant holders and project staff
from the Clinical Co-coordinating Centre at the Royal
Brompton Hospital NHS Trust and the Data Co-coordi-
nating Centre (DCC) at the LSHTM.
Publication policy
To safeguard the integrity of the trial, data from this
study will not be presented in public or submitted for
publication without requesting comments and receiving
agreement from the Trial Steering Committee. The pri-
mary results of the trial will be published by the group
as a whole with local investigators acknowledged. The
success of the trial depends on the collaboration of
many people. The results will be presented first to the
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trial local investigators. A summary of the results of the
trial will be sent to parents of participating children on
request and also made available on the trial website.
Confidentiality
Patients will be identified by their trial number to
ensure confidentiality. However, as the patients in the
trial will be followed up to 12 months following rando-
misation, it is essential that the team at the Data Co-
coordinating Centre has the names and addresses of the
trial participants recorded on the data collection forms
in addition to the allocated trial number. Stringent pre-
cautions will be taken to ensure confidentiality of names
and addresses at the Data Co-coordinating Centre.
The Chief Investigator and local investigators will
ensure conservation of records in areas to which access
is restricted.
Audit
To ensure that the trial is conducted according to ICH
GCP guidelines, site audits will be carried out on a ran-
dom basis. The local investigator will be required to
demonstrate knowledge of the trial protocol and proce-
dures and Good Clinical Practice. The accessibility of
the site file to trial staff and its contents will be checked
to ensure all trial records are being properly maintained.
Adherence to local requirements for consent will be
examined.
If the site has full compliance the Site Visit Form will
be signed by the Trial Manager. In the event of non-
compliance the Data Coordinating Centre will address
the specific issues to ensure that relevant training and
instruction is given.
Termination of the study
At the termination of planned recruitment the Data Co-
coordinating Centre will contact all sites by telephone,
email or fax in order to terminate all patient recruitment
as quickly as possible. If the study is terminated prema-
turely by the Steering Committee all sites will be informed
immediately. When all recruited patients have been fol-
lowed until 30 days post randomisation (or hospital dis-
charge if stay longer than 30 days) a declaration of the end
of trial form will be sent to EurdraCT and the MREC. The
following documents: original consent forms, original data
forms, trial related documents and correspondence will be
archived in each Site File and kept for at least five years.
At the end of the analysis and reporting phase, the Trial
Master Files at the Clinical and Data Co-coordinating
Centres will be archived for 15 years.
Indemnity
If there is negligent harm during the clinical trial when
the NHS body owes a duty of care to the person
harmed, NHS Indemnity covers NHS staff, medical aca-
demic staff with honorary contracts, and those conduct-
ing the trial. NHS Indemnity does not offer no-fault
compensation.
Discussion
Data from level 2 trials have driven the adult intensive
care clinicians to adopt treatment regimes that favour
tight glycaemic control. Equipoise presently exists in the
paediatric intensive care community and this allows us a
very important opportunity to conduct an adequately
powered randomised controlled trial in this setting.
Data monitoring committee
Professor David Dunger (CHAIR), Department of Pae-
diatrics, University of Cambridge; Dr David Harrison,
Statistician, Intensive Care Audit and Research Network
(ICNARC); Professor David Hatch, Emeritus Professor
of Paediatric Anaesthesia and Intensive Care, Great
Ormond Street Hospital; Mr. Giles Peek, Consultant
Cardiac Surgeon, Glenfield Hospital, Leicester (until
2009);
Dr Jon Smith, Consultant Paediatric Cardiothoracic
Anaesthetist, Freeman Hospital, Newcastle (from 2009).
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